Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...

Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...